Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Opdivo

PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug
Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Opdivo Recent News

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Mirati Therapeutics Sitravatinib Data, Explained
Mirati Therapeutics Sitravatinib Data, Explained
The Most Notable Abstracts Released Ahead Of ASCO 2017
The Most Notable Abstracts Released Ahead Of ASCO 2017
Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge
Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge
Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers
Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers
Which Pharma Players Dominate The Lung Cancer Space?
Which Pharma Players Dominate The Lung Cancer Space?
Here's What Merck's Keytruda News Means For Bristol-Myers
Here's What Merck's Keytruda News Means For Bristol-Myers
This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
Bristol-Myers Opdivo Vs. Merck's Keytruda In Front Line Lung Treatment
Bristol-Myers Opdivo Vs. Merck's Keytruda In Front Line Lung Treatment
SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower
SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower
Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
JPMorgan's Take On Big Pharma's New ASCO Abstracts
JPMorgan's Take On Big Pharma's New ASCO Abstracts
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved